 |
|
|
|
|
|
 |
|
|
International Experience and Controversies
Tuesday, September 25th, 2007
|
|
14:00 |
Welcome and introduction to the program
Michael Schlander
|
14:30 |
Economic welfare theory and health economics
Friedrich Breyer
|
15:30 |
The logic of cost-effectiveness ("extra-welfarism")
Martin J. Buxton
|
|
|
16:30 |
Coffee Break
|
|
|
17:00 |
The ethics of priority setting in health care
Sören Holm
|
18:00 |
Re-interpreting health economics
Jeff Richardson
|
|
|
19:00 |
Supper Break
|
|
|
20:00 |
Roundtable discussion:
The "dismal science" revisited:
Normative foundations of health economic analysis
Friedrich Breyer
Martin J. Buxton
Sören Holm
Jeff Richardson
Michael Schlander
|
|
|
 |
|
|
 |
|
|
|
|
Wednesday, September 26th, 2007
|
|
9:00 |
National Institute for Health and Clinical Excellence (NICE)
Martin J. Buxton
- Mission and roles of NICE
- The NICE reference case
- NICE processes and procedures
- How does NICE come to its decisions?
- How do NICE and the Scottish Medicines Consortium (SMC) relate?
|
10:30 |
Coffee Break
|
11:00 |
NICE and the National Health Service (NHS)
Martin J. Buxton
- Implementation issues
- Is the current ICER threshold right?
- Value-based pricing - possible future developments
|
12:30 |
Lunch Break
|
14:00 |
The Australian experience
Rosalie Viney and Jeff Richardson
- Pharmaceutical Benefits Scheme (PBS) in Australia
- Pharmaceutical Benefits Advisory Committee (PBAC)
- Quality of submissions to PBAC - common flaws
- Can the system be "played" by companies?
|
15:30 |
Coffee Break
|
16:00 |
The Canadian experience
Andreas Laupacis
- The Canadian Common Drug Review (CDR)
- CDR appraisal processes
- Canadian Expert Drug Advisory Committee (CEDAC) Canadian Agency for Drugs and Technologies in Health (CADTH)
- Provincial formulary listing in Canada
|
17:30 |
Break
|
19:00 |
Social program & dinner
|
|
|
 |
|
|
|
|
|
|
|
Thursday, September 27th, 2007
|
|
9:00 |
Economic analysis and medical decision-making: help or hindrance? A North American perspective
Andreas Laupacis
- Prescription creep and implementation issues
- Usefulness of economic evaluations
- Canadian drug policy and pharmacoeconomics
- Expensive drugs for rare diseases in Canada
- Recent trends in the United States
|
10:30 |
Coffee Break
|
11:00 |
Health Technology Assessments in Europe
Panos Kanavos
- Assessment procedures and methods in Europe
- HTAs and decision-making in Europe
- Evidence and innovation in health care
- Interface between HTAs and innovation
|
12:30 |
Lunch Break
|
14:00 |
Pharmaceutical price regulation in the UK
Panos Kanavos
- Reforming the UK Pharmaceutical Price Regulation Scheme (PPRS)
- Moving towards value-based pricing in the UK?
- Implications for stakeholders
|
15:00 |
The Swedish experience
Ulf Persson
- The Pharmaceutical Benefits Board (LNF)
- Applying the cost-effectiveness principle
- Experience, issues and debate in Sweden
|
16:30 |
Coffee Break
|
17:00 |
The German approach to economic evaluation
Peter Kolominsky-Rabas
- Legal and regulatory environment
- Mission and roles of IQWiG
- HTAs in Germany
- Objectives of health economic evaluations by IQWiG
|
18:30 |
Supper Break
|
20:00 |
Roundtable discussion:
Value-based pricing: a NICE approach?
Andreas Laupacis
Panos Kanavos
Peter Kolominsky-Rabas
Ulf Persson
Michael Schlander
|
|
|
 |
|
|
|
|
|
|
|
Friday, September 28th, 2007
|
|
9:00 |
Stakeholder expectations I
Koen Torfs
- A research-based pharmaceutical corporation’s view
|
10:00 |
Christine Lavery
- The perspective of patients
|
11:00 |
Coffee Break
|
11:30 |
Stakeholder expectations II
Wolfgang Kaesbach
- The perspective of payers in the regulatory context
|
12:30 |
Discussion
|
13:00 |
Which way forward?
Michael Schlander
- What have we learnt?
- Concluding remarks
|
13:30 |
Lunch (optional)
|
|
|
 |
|
|
|
|
|
|
|
Disclaimer
|
|
|
|
|
|
|
|
|
